PRIMARY BREAST CANCER THERAPY GROUP--NSABP

原发性乳腺癌治疗组

• 批准号: 3556456
• 负责人: HARVEY J LERNER
• 金额: $ 5.15万
• 依托单位: PENNSYLVANIA HOSPITAL (PHILADELPHIA)
• 依托单位国家: 美国
• 财政年份: 1977
• 资助国家: 美国
• 起止时间: 1977-02-01 至 1991-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556456
• 关键词: Corynebacterium; breast neoplasms; combination chemotherapy; cooperative study; drug adverse effect; fluorouracil; human subject; human therapy evaluation; methotrexate; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery

As a participting institution in the Primary Breast Cancer Therapy Group (NSABP) we are contributing data from patients entered into the various group protocols. Patients have been entered into Protocol 5, which compared L-PAM with L-PAM and 5-FU, and Protocol 8, which compared the worth of 3 drug chemotherapy (L-PAM, 5-FU, and MTX) with a 2 drug chemotherapy (L-PAM and 5-FU). Protocol No. 6: A trial to compare the worth of segmental mastectomy with and without breast radiation with total mastectomy plus axillary dissection. All patients will undergo axillary dissection and those with histologically positive axillary nodes will receive adjuvant chemotherapy. Protocol No. 9: A trial to determine whether the anti-estrogen Tamoxifen when combined with chemotherapy improves the results obtained with chemotherapy alone. In addition, the NSABP has implemented adjuvant protocols for primary colon and rectal carcinoma. The present application seeks funding (a) to permit continued patient accrual in on-going protocols, (b) to continue follow-up of patients entered into protocols which have terminated, and (c) to collect appropriate biological material and information relevant to such protocols. Finally, the aim of this proposal is to enhance the multidisciplinary approach of this institution in these clinical trials.

作为初级乳腺癌治疗组 (NSABP) 的参与机构 我们正在贡献来自加入各个小组协议的患者的数据。 患者已加入协议 5，该协议将 L-PAM 与 L-PAM 进行比较， 5-FU 和方案 8，比较了 3 种药物化疗（L-PAM、 5-FU 和 MTX）联合 2 种药物化疗（L-PAM 和 5-FU）。 方案 6：A 比较带乳房和不带乳房的部分乳房切除术价值的试验 全乳房切除术加腋窝淋巴结清扫术进行放射治疗。 所有患者都会 进行腋窝淋巴结清扫术以及组织学阳性的腋窝淋巴结清扫术 淋巴结将接受辅助化疗。 方案 9：试验以确定 抗雌激素他莫昔芬与化疗联合使用是否可以改善 单独化疗获得的结果。 此外，国家安全局还 实施原发性结肠癌和直肠癌的辅助方案。 这 本申请寻求资金 (a) 以允许继续增加患者 正在进行的方案，(b) 继续对签订方案的患者进行随访 已终止，以及 (c) 收集适当的生物材料和 与此类协议相关的信息。 最后，本提案的目的是 加强该机构在这些临床方面的多学科方法 试验。